Sarala Balachandran

TL;DR: Three different series of pyrazolo[3,4-b]pyridines and their structural analogues are synthesized using novel synthetic strategy involving one-pot condensation of 5, 6-dihydro-4H-pyran-3-carbaldehyde/2-formyl-3, 4,6-tri-O-methyl-D-glucal/chromone-3

TL;DR: In this article, isoxazoline derivatives of structure (I) can be used as selective inhibitors of PDE type IV, which can be useful in the treatment of AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis and other inflammatory diseases in a patient.

TL;DR: In this paper, the authors investigated and compared the activity of representative MIF inhibitors from isoxazole series (fluorinated analog of ISO-1; ISO-F) and substituted quinoline series (compound 7E; 7E).

TL;DR: Dacylphloroglucinol compounds as a new class of GPR40 (FFAR1) agonists with varying length of acyl functionality and substitution on aromatic hydroxyls are reported.

TL;DR: NIS-62949 is a potent, highly selective PDE4 inhibitor that demonstrated potent ability to inhibit tumor necrosis factor-α release from human peripheral blood mononuclear cells, lymphocyte proliferation and cytokine production and displayed a safer profile compared to roflumilast.